$SMMTSummit Therapeutics Inc.

📅 Upcoming

🕒 Recent(90d)

News

• Merck’s Moderna-partnered vaccine success clears view of post-Keytruda future
  Investors had been pessimistic about the probability of success for the personalized cancer vaccine intismeran autogene, so the Phase 3 win was a welcome surprise.
  biospace · 17h ago
• Amylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, more
  Amylyx shares good news for its investigational GLP-1 blocker; Definium announces positive data for its LSD-based therapy in anxiety; Summit/Akeso’s ivonescimab shows degrading survival benefits; p…
  biospace · 1d ago
• Summit, Akeso's ivonescimab shows smaller benefit with longer follow-up in China
  Summit Therapeutics and Akeso’s next-generation cancer drug ivonescimab earned an approval in China last week for first-line patients with certain forms of lung cancer. But it came with an updated…
  endpoints · 3d ago
• Summit, Akeso’s China approval celebration cut short as survival benefit degrades
  Ivonescimab notched its third approval in China last week, but the label update has tempered expectations for the Summit Therapeutics/Akeso drug, showing that progression-free survival declines ove…
  biospace · 3d ago
• STAT+: Akeso and Summit’s lung cancer drug shows worsening tumor-progression benefit
  Europe pulls Tavneos over trial integrity concerns, pricing concerns over AstraZeneca's hypertension drug, and more biotech news from The Readout
  stat · 3d ago
• Merck posts—then pulls—trial plan for PD-1xVEGF and TROP2 ADC combination
  After keeping tight-lipped for nearly two years, Merck & Co. briefly dropped the first concrete hint as to where it intends to take its PD-1xVEGF bispecific antibody—before quietly scrubbing the ev…
  fiercebiotech · 22d ago
• As pharma descends on China for deals, BIOSECURE Act raises intellectual property risk
  When signing a biotech licensing deal in China, experts say that pharma’s patent attorneys need to understand the geopolitical risk of the BIOSECURE Act.
  biospace · 24d ago
• Summit, Merck must navigate new regulatory terrain in China-first cancer landscape
  Summit Therapeutics revealed positive Western data last week from a Phase 3 trial of lung cancer candidate ivonescimab. In a flipped geographical clinical trials landscape, what more will be requir…
  biospace · 25d ago
• Summit has less than a year of cash runway left as PD-1/VEGF verdict nears
  Summit’s star asset is the PD-1/VEGF bispecific ivonescimab, which this week produced promising survival data from a late-stage global trial in non-small cell lung cancer. The FDA review is ongoing…
  biospace · 27d ago
• Summit and Akeso sharpen case for ivonescimab with new Western data
  Summit Therapeutics and Akeso are answering questions raised about ivonescimab’s ability to translate to Western populations, though the partners have yet to share if the new findings are statistic…
  biospace · 29d ago